Class Actions
Lululemon Athletica Inc. Class Action
Robbins LLP is Investigating Allegations that Lululemon Athletica Inc. (LULU) Misled Investors Regarding its Inventory Allocation Issues
August 8, 2024
THE NEWSROOM
Search
Categories
Archives
Investment Monitoring From Robbins LLP
To ensure your financial investments are being managed honestly, enroll in Stock Watch, our free investment monitoring service for individual and institutional investors.
Class Actions
Indivior PLC Class Action
Robbins LLP is Investigating Allegations that Indivior PLC (INDV) Misled Investors Regarding the Financial Prospects of its Products
August 7, 2024
Class Actions
Lifecore Biomedical, Inc. Class Action
Robbins LLP is Investigating Allegations that Lifecore Biomedical, Inc (LFCR) Misled Investors Regarding its Internal Controls Over Financial Reporting
August 6, 2024
Robbins LLP News
What is the correlation between the stock market and the bond market?
If you have ever wondered about the definitions of bonds and stocks, and the interplay between the two investment vehicles, this blog is for you.
August 5, 2024
Class Actions
DXC Technology Company Class Action
Robbins LLP is Investigating Allegations that DXC Technology Company (DXC) Misled Investors Regarding its Operations and Financial Health
August 2, 2024
Class Actions
Five Below, Inc. Class Action
Robbins LLP is Investigating Allegations that Five Below, Inc. (FIVE) Misled Investors Regarding its Operations and Financial Health
August 1, 2024
Class Actions
Arbor Realty Trust, Inc. Class Action
Robbins LLP is Investigating Allegations that Arbor Realty Trust, Inc. (ABR) Misled Investors Regarding its Operation and Financial Health
July 31, 2024
Class Actions
CrowdStrike Holdings, Inc. Class Action
Robbins LLP is Investigating Allegations that CrowdStrike Holdings, Inc. (CRWD) Misled Investors Regarding the Efficacy of its Falcon Product
July 31, 2024
Class Actions
MacroGenics, Inc. Class Action
Robbins LLP is Investigating Allegations that MacroGenics, Inc. (MGNX) Misled Investors Regarding the Viability of its Drug Candidate
July 30, 2024
Protect your